Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CPA1 | P15085 | 6/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8694632 | 0.94 | EPHX2 (0.38) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL15083099 | 0.83 | PPARG (0.43) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL29540316 | 0.83 | PPARG (0.43) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL16288980 | 0.83 | PPARG (0.43) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL30744235 | 0.83 | PPARG (0.43) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL118926 | 0.81 | ITGB3 (0.45) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL7100601 | 0.81 | FABP5 (0.43) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL120592 | 0.81 | ITGB3 (0.45) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL120595 | 0.81 | ITGB3 (0.45) | FABP5FABP7KMT2APPARGPPARA | |
| SCHEMBL29633817 | 0.81 | ITGB3 (0.45) | FABP5FABP7KMT2APPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114514-A1 | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses | BIOGEN IDEC MA INC. | 2003-06-19 | — | — | US | disclosed |
| EP-1253923-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA 1 INTEGRIN COMPOUNDS AND USES | BIOGEN, INC. (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001054690-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA 1 INTEGRIN COMPOUNDS AND USES | BIOGEN, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114514-A1 | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses | ITGB1, ITGA1, ITGB2 | FABP5 2044/4885FABP7 2202/4885KMT2A 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.